Ret Proto-Oncogene antibody

Catalog No. ABIN1882126

Product Details anti-Ret Proto-Oncogene Antibody

Target: Ret Proto-Oncogene (RET)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Ret Proto-Oncogene antibody is un-conjugated

Application: Western Blotting (WB)

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This RET antibody is generated from rabbits immunized with His fusion protein of human RET.

Clone: RB17715

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Expiry Date: 6 months

References for anti-Ret Proto-Oncogene antibody (ABIN1882126)

Siqueira, Romitti, da Rocha, Ceolin, Meotti, Estivalet, Puñales, Maia: "The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma." in: Endocrine-related cancer, Vol. 17, Issue 4, pp. 953-63, (2010) (PubMed).

Gockel, Schumacher, Gockel, Lang, Haaf, Nöthen: "Achalasia: will genetic studies provide insights?" in: Human genetics, Vol. 128, Issue 4, pp. 353-64, (2010) (PubMed).

Kim, Jung, Lim, Sung, Whang, Jo, Lee, Shin, Kim, Ryu, Kim: "A study of RET proto-oncogene polymorphisms in association with lung cancer risk in the Korean population." in: Anticancer research, Vol. 30, Issue 9, pp. 3621-7, (2010) (PubMed).

Pacini, Castagna, Cipri, Schlumberger: "Medullary thyroid carcinoma." in: Clinical oncology (Royal College of Radiologists (Great Britain)), Vol. 22, Issue 6, pp. 475-85, (2010) (PubMed).

Target Details for Ret Proto-Oncogene

Target: Ret Proto-Oncogene (RET)

Alternative Name: RET (RET Products)

Synonyms: c-ret antibody, cret antibody, etID315074.13 antibody, ret1 antibody, wu:fd13h01 antibody, X-ret antibody, ret-A antibody, xret antibody, RET antibody, MTC1 antibody, CDHF12 antibody, CDHR16 antibody, HSCR1 antibody, MEN2A antibody, MEN2B antibody, PTC antibody, RET-ELE1 antibody, RET51 antibody, RET9 antibody, c-Ret antibody, ret proto-oncogene receptor tyrosine kinase antibody, ret proto-oncogene S homeolog antibody, ret proto-oncogene antibody, ret antibody, ret.S antibody, RET antibody, Ret antibody

Background: This gene, a member of the cadherin superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This gene plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in this gene are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. Two transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their biological validity has not been confirmed.

Molecular Weight: 124319

NCBI Accession: NP_065681, NP_066124

UniProt: P07949

Pathways: RTK Signaling, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation